Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.

Calliditas Therapeutics AB

CALT
40,0001
0,00 (0,00%)
Ultimo aggiornamento: 01:00:00
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
23/9/202422:44EDGAR2Form 15F-12B - Securities registration termination of..
16/9/202415:46PRNUSDelisting of Calliditas Therapeutics AB (publ) from Nasdaq..
03/9/202413:13PRNUSNotice of extraordinary meeting of Calliditas Therapeutics..
03/9/202412:33PRNUSCalliditas Therapeutics takes certain corporate actions..
03/9/202412:31PRNUSCalliditas Therapeutics takes certain corporate actions..
13/8/202407:25PRNUSCalliditas Interim Report January to June 2024
13/8/202407:22PRNUSCalliditas Interim Report January to June 2024
05/8/202407:26PRNUSInvitation to the presentation of Calliditas´s interim..
05/8/202407:19PRNUSInvitation to the presentation of Calliditas´s interim..
01/8/202415:00GLOBECalliditas Therapeutics to Attend 2024 Women in Nephrology..
31/7/202414:23PRNUSNumber of shares and votes in Calliditas Therapeutics
26/7/202422:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/7/202417:23PRNUSCalliditas partner STADA receives European Commission..
26/7/202417:21PRNUSCalliditas partner STADA receives European Commission..
26/7/202408:29PRNUSCalliditas announces positive TRANSFORM Phase 2b topline..
26/7/202408:23PRNUSCalliditas announces positive TRANSFORM Phase 2b topline..
04/7/202409:44PRNUSLaunch of Phase 3 clinical trial with Nefecon in Japan
04/7/202409:20PRNUSLaunch of Phase 3 clinical trial with Nefecon in Japan
18/6/202412:25PRNUSCalliditas provides setanaxib patent update
18/6/202412:23PRNUSCalliditas provides setanaxib patent update
17/6/202418:01PRNUSBulletin from the annual general meeting of Calliditas..
30/5/202422:52EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/5/202420:20PRNUSCalliditas partner STADA receives positive CHMP opinion..
30/5/202420:18PRNUSCalliditas partner STADA receives positive CHMP opinion..
28/5/202414:46PRNUSCalliditas Therapeutics Presents Data at the 61st European..
28/5/202414:36PRNUSCalliditas Therapeutics Presents Data at the 61st European..
28/5/202414:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/5/202414:09EDGAR2Form SC14D9C - Written communication relating to third party..
28/5/202409:17PRNUSStatement by the Board of Directors of Calliditas..
28/5/202409:14PRNUSStatement by the Board of Directors of Calliditas..
23/5/202422:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/5/202407:55PRNUSCalliditas Q1 report, January - March 2024
23/5/202407:52PRNUSCalliditas Q1 report, January - March 2024
16/5/202422:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/5/202408:45PRNUSInvitation to the presentation of Calliditas´s interim..
16/5/202408:43PRNUSInvitation to the presentation of Calliditas´s interim..
15/5/202414:30PRNUSCalliditas Therapeutics to Present Data at ERA 2024 May 23 -..
15/5/202414:24PRNUSCalliditas Therapeutics to Present Data at ERA 2024 May 23 -..
15/5/202413:36PRNUSNotice of annual general meeting of Calliditas Therapeutics..
15/5/202413:30PRNUSNotice of annual general meeting of Calliditas Therapeutics..
14/5/202413:52PRNUSCalliditas' Partner Everest Medicines Starts Commercial..
14/5/202413:35PRNUSCalliditas' Partner Everest Medicines Starts Commercial..
06/5/202408:16PRNUSCalliditas announces positive topline results of Phase 2..
06/5/202408:11PRNUSCalliditas announces positive topline results of Phase 2..
24/4/202419:35PRNUSCalliditas Therapeutics' 2023 Annual Report Published
24/4/202419:26PRNUSCalliditas Therapeutics' 2023 Annual Report Published
24/4/202409:30PRNUSCalliditas Announces Positive NefIgArd Open Label Extension..
24/4/202409:26PRNUSCalliditas Announces Positive NefIgArd Open Label Extension..
18/4/202413:13PRNUSCalliditas Therapeutics Presents Additional Data Analyses..
18/4/202413:10PRNUSCalliditas Therapeutics Presents Additional Data Analyses..
Apertura: Min: Max:
Chiusura: 40,0001

La tua Cronologia

Delayed Upgrade Clock

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network